Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Pembrolizumab for dMMR Solid Cancers
NCT04082572Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Oct 2019
- Primary completion
- Nov 2024
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in solid tumor, sponsored by University of Texas MD Anderson Cancer Center. Started Oct 2019; status: completed.
02
Drugs
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04082572.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04082572.